Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.

Blood - 22 Jan 2009

Yong Agnes S M, Keyvanfar Keyvan, Hensel Nancy, Eniafe Rhoda, Savani Bipin N, Berg Maria, Lundqvist Andreas, Adams Sharon, Sloand Elaine M, Goldman John M, Childs Richard, Barrett A John

Abstract excerpt

Primitive quiescent CD34(+) chronic myeloid leukemia (CML) cells are more biologically resistant to tyrosine kinase inhibitors than their cycling counterparts; however, graft-versus-leukemia (GVL) effects after allogeneic stem cell transplantation (SCT) probably eliminate even these quiescent cells in long-term surviving CML transplant recipients. We studied the progeny of CD34(+) cells from CML patients before...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Boronic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bortezomib

Share to Cell Separation

Share to Killer Cells, Natural

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Monomeric GTP-Binding Proteins

Share to Pyrazines

Source

Open in PubMed Open full text

Identifiers

PMID: 18922853
DOI: 10.1182/blood-2008-05-158253
PMCID: PMC2630272

Genes

SCT
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.PMID 18922853Read ↗

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?Semantic proximity Read ↗

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.Semantic proximity Read ↗

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitroSemantic proximity Read ↗

Transcriptional Analysis of Quiescent and Proliferating CD34+ Human Hemopoietic Cells from Normal and Chronic Myeloid Leukemia SourcesSemantic proximity Read ↗

Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia.Semantic proximity Read ↗

Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.Semantic proximity Read ↗

Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.Semantic proximity Read ↗

Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemiaSemantic proximity Read ↗

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatmentSemantic proximity Read ↗

Activation of quiescent ABL-transduced hemopoietic stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.